Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Prices Offering of Euro-denominated Senior Notes

NEW YORK(GenomeWeb) – Thermo Fisher Scientific on Monday after the close of the market priced its offering of €640 million ($797 million) of 2 percent senior notes due 2025 at an issue price of 99.68 percent of the principal amount.  

The issuance of the notes is expected to close on or about Nov. 24. The company plans to use net proceeds mainly to repay about $70 million of short-term indebtedness and to repay about $600 million of long-term indebtedness, which consists of outstanding amounts under the company's $5 billion term loan.  

Thermo Fisher filed a prospectus for the euro-denominated offering of the senior notes last week. On Friday, the company issued $800 million in aggregate principal amount of 3.3 percent senior notes due in 2022. 

The joint book-running managers on the offering are HSBC Bank, Deutsche Bank Securities, and RBS Securities.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.